Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue

Impact · against what's priced in

Allarity Therapeutics has established a viable secondary revenue stream through its CLIA laboratory services, reducing dependence on clinical trial milestones. While the company remains a speculative bet on Stenoparib, this first commercial contract provides a modest floor of recurring revenue that was not previously realized.

ALLR+0.40

No priced-in read yet